1. Short title This Act may be cited as the Expanding Cannabis Research and Information Act . 2. Cannabis research at the Department of Health and Human Services (a) National cannabis research agenda Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.) is amended by adding at the end the following: 409K. National cannabis research agenda Not later than 1 year after the date of enactment of the Expanding Cannabis Research and Information Act , the Director of NIH, in collaboration with the Director of the Centers for Disease Control and Prevention and the Assistant Secretary for Mental Health and Substance Use, shall develop a national cannabis research agenda that addresses key questions and gaps in evidence, including with respect to each of the following: (1) The efficacy of cannabis in providing therapeutic benefits for certain priority diseases or conditions, which may include epilepsy, multiple sclerosis-related spasticity, chemotherapy-induced pain and discomfort, using cannabis as an alternative to opioid analgesics for acute or chronic pain, sleep apnea, Tourette syndrome, anxiety, post-traumatic stress disorder, and any other disease or condition determined to be appropriate and of importance by the Director. (2) The effect of cannabis on at-risk populations, including children, older individuals, and pregnant or breast-feeding women. (3) The long-term effects of cannabis use, including dose-response relationship and the connection between cannabis use and behavioral health. (4) The clinically appropriate modes of delivery of cannabis. (5) Public safety considerations related to cannabis, including— (A) variation in the potency of cannabis products; (B) youth access to and use of cannabis, including marketing, packaging, edible formulations, and flavor options that target youth; (C) risk factors for cannabis misuse; (D) impaired driving related to cannabis use